Biogen Is Celebrating A First In Alzheimer's Disease. But Investors Are Leery.Investors Business Daily • 05/14/26
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's DiseaseGlobeNewsWire • 05/14/26
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/13/26
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's DiseasePRNewsWire • 05/08/26
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600PRNewsWire • 05/07/26
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesBusiness Wire • 05/07/26
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A CostsZacks Investment Research • 04/29/26
Compared to Estimates, Biogen (BIIB) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 04/29/26
Biogen Walloped Wall Street's First Quarter Views; Here's What HappenedInvestors Business Daily • 04/29/26
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?Zacks Investment Research • 04/24/26
Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to DeclineZacks Investment Research • 04/22/26
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?24/7 Wall Street • 04/22/26
BIIB Inks Deal to Acquire Rights to Felzartamab in China, Stock UpZacks Investment Research • 04/21/26